About: Modulating the transcriptional landscape of SARS-CoV-2 as an effective method for developing antiviral compounds

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Modulating the transcriptional landscape of SARS-CoV-2 as an effective method for developing antiviral compounds Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Modulating the transcriptional landscape of SARS-CoV-2 as an effective method for developing antiviral compounds
Creator	Lee, Benhur Han, Yuling Lachmann, Alexander Tenoever, Benjamin Chen, Shuibing Hoagland, Daisy Møller, Rasmus Oguntuyo, Kasopefoluwa Stevens, Christian Yang, Liuliu Clarke, Daniel Ma'ayan, Avi Wojciechowicz, Megan
Source	BioRxiv
abstract	To interfere with the biology of SARS-CoV-2, the virus responsible for the COVID-19 pandemic, we focused on restoring the transcriptional response induced by infection. Utilizing expression patterns of SARS-CoV-2-infected cells, we identified a region in gene expression space that was unique to virus infection and inversely proportional to the transcriptional footprint of known compounds characterized in the Library of Integrated Network-based Cellular Signatures. Here we demonstrate the successful identification of compounds that display efficacy in blocking SARS-CoV-2 replication based on their ability to counteract the virus-induced transcriptional landscape. These compounds were found to potently reduce viral load despite having no impact on viral entry or modulation of the host antiviral response in the absence of virus. RNA-Seq profiling implicated the induction of the cholesterol biosynthesis pathway as the underlying mechanism of inhibition and suggested that targeting this aspect of host biology may significantly reduce SARS-CoV-2 viral load.
has issue date	2020-07-13(xsd:dateTime)
bibo:doi	10.1101/2020.07.12.199687
has license	biorxiv
sha1sum (hex)	49e91a7f9fd64a1e3ab99e07fa9353a8a2ee2d14
schema:url	https://doi.org/10.1101/2020.07.12.199687
resource representing a document's title	Modulating the transcriptional landscape of SARS-CoV-2 as an effective method for developing antiviral compounds
schema:publication	bioRxiv
resource representing a document's body	covid:49e91a7f9fd64a1e3ab99e07fa9353a8a2ee2d14#body_text
is schema:about of	named entity 'cholesterol' named entity 'Here' named entity 'SARS-CoV-2' named entity 'transcriptional' named entity 'blocking' named entity 'PATHWAY' named entity 'REGION' named entity 'KNOWN' covid:arg/49e91a7f9fd64a1e3ab99e07fa9353a8a2ee2d14 named entity 'pandemic' named entity 'efficacy' named entity 'infection' named entity 'reduce' named entity 'targeting' named entity 'host' named entity 'transcriptional' named entity 'viral entry' named entity 'successful' named entity 'replication' named entity 'ability' named entity 'viral load' named entity 'expression patterns' named entity 'SARS-CoV-2' named entity 'antiviral' named entity 'SARS-CoV-2' named entity 'antiviral' named entity 'effective method' named entity 'compounds' named entity 'FDA' named entity 'gene expression' named entity 'small molecules' named entity 'endocrine' named entity 'Chlorpromazine' named entity 'multi-omics' named entity 'orders of magnitude' named entity 'SARS-CoV-2' named entity 'Epstein-Barr virus' named entity 'recombinant' named entity 'A549' named entity '3' end' named entity 'molecular basis' named entity 'cell types' named entity 'transcriptional' named entity 'student's t-test' named entity 'cell-based assays' named entity 'immune response' named entity 'Epstein-Barr virus' named entity 'epithelial' named entity 'A549' named entity 'passaging' named entity 'gene' named entity 'toxicity' named entity 'terfenadine' named entity 'infection' named entity 'approved drugs' named entity 'virus' named entity 'cholesterol' named entity 'Ebola' named entity 'nucleocapsid' named entity 'loperamide' named entity 'cholesterol' named entity 'blood pressure' named entity 'A549' named entity 'viral entry' named entity 'transcriptional' named entity 'cell cycle' named entity 'Loperamide' named entity 'virus' named entity 'DMSO' named entity 'viral infection' named entity 'inflammatory' named entity 'virus infection'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software